Statins: risks, nocebo & the overtreatment debate

Muscle aches are the most-cited complaint — but blinded N-of-1 trials (SAMSON, StatinWISE) found the great majority of perceived statin muscle symptoms are nocebo: people got the same aches on placebo. True pharmacological myopathy is real but uncommon; rhabdomyolysis is very rare. New-onset diabetes is real — roughly one extra case per ~200 person-years at high intensity, dose-related, and mostly in people already prediabetic. Liver-enzyme bumps are usually benign; the 'brain fog' signal hasn't held up in trials. So the risks are real but modest, and the scariest anecdotes are largely nocebo. Evidence ●●●●○

Thoughtful critics — writers around Redberg & Abramson in the BMJ, Robert DuBroff, and others — argue that in low-risk primary prevention the absolute benefit is tiny (some estimates put it at deferring an event by days), that relative-risk headlines ('36% reduction!') oversell a small absolute gain, that much trial data is industry-run with patient-level data not fully open, and that healthy low-risk people get needlessly medicalised. On the narrow point of over-treating the low-risk, this critique has real force. (Where some go too far — denying that LDL causes disease — the evidence is firmly against them; keep those claims separate.)

The counter, from the CTT collaboration and most cardiologists: the causal case for LDL is overwhelming (Mendelian randomisation plus trials line up), the harms are genuinely low and mostly nocebo, and the 'days of life' framing understates benefit because it ignores the non-fatal heart attacks and strokes prevented along the way. Notably, even most defenders now agree that low-risk primary prevention should be a shared decision rather than a blanket mandate — and that a calcium score can personalise it.

Strip away the heat and the facts are agreed: LDL causes plaque (settled), and statins lower it and prevent events (settled). The real disagreement is narrower — the size of the benefit for low-risk people and how honestly it's communicated. That's a values-and-communication question, not a factual one. The way through is your own real risk (ideally with a calcium score), decided with your clinician — not a headline and not a podcast.